IW 1701

Drug Profile

IW 1701

Alternative Names: IW-1701; sGC stimulator - Ironwood

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal disorders
  • Phase I Cardiovascular disorders; Fibrosis

Most Recent Events

  • 03 Nov 2016 Phase-II clinical trials in Gastrointestinal disorders in USA (PO) (NCT02931565)
  • 01 Nov 2016 Ironwood Pharmaceuticals completes a phase Ib trial (In volunteers) in USA (NCT02792998)
  • 12 Oct 2016 Ironwood Pharmaceuticals plans a phase II trial in Achalasia in USA (NCT02931565)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top